Category Archives: Transhuman News

The demand within the global spatial genomics and transcriptomics market is expanding at a stellar pace in the years to follow. Advancements in molecular biology have paved the way for revenue inflow into the global spatial genomics and transcriptomics market. The need for studying genetic patterns in humans, animals, and plants has generated new opportunities for market expansion, Genetic engineering has emerged as a robust domain within nascent biological sciences, creating room for experimentation and analysis. The applications of genomics in molecular biology and genetic studies has given a thrust to market expansion.

In this custom review, TMR Research delves into the extrinsic and intrinsic trends that are shaping the growth graph of the global spatial genomics and transcriptomics market. The domain of biological sciences has encapsulated new technologies for studying sizes, compositions, and archetypes of human genes. This is playing a vital role in driving sales across the global spatial genomics and transcriptomics market. This review also assesses the impact of advancements in genetic engineering to decode market growth.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=7053

Spatial Genomics & Transcriptomics Market: Notable Developments

Key Players

Spatial Genomics & Transcriptomics Market: Growth Drivers

The high incidence of genetic disorders has probed the medical industry to invest in new technologies for genetic engineering and gene transfer studies. Several medical centers and research units are investing in the study of dyslexia, downs syndrome, and other genetic inconsistencies. This has created fresh avenues for growth across the global spatial genomics and transcriptomics market. In addition to this, the use of next-generation genetic studies for understanding genetic disorders has also given a thrust to market expansion.

The importance of microbiology in genetic studies has created a boatload of opportunities for growth and expansion across the global spatial genomics and transcriptomics market. The use of spatial genomics to understand the structure and composition of genes has enabled the inflow of fresh revenues into the global market. Besides, the use of genetic studies in the domain of veterinary care has also generated humongous opportunities for market expansion. The study of human and animal genes often goes hand-in-hand for the purpose of core research and analysis.

Get Table of Content of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=7053

Regional Segments

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

Rohit Bhisey

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

Visit link:
Spatial Genomics & Transcriptomics Market Demand is Expanding at a Stellar Pace in the Years to Follow - BioSpace

By: Explained Desk | New Delhi | Updated: December 19, 2020 12:45:50 pmThis undated photo provided by Revivicor, Inc., a unit of United Therapeutics, shows a genetically modified pig. (Revivicor, Inc. via AP)

This week, the US Food and Drug Administration (FDA) approved a first-of-its-kind intentional genomic alteration (IGA) in a line of domestic pigs referred to as GalSafe pigs. These pigs may be used for food and human therapeutics, the FDA has said. This will be the first time that the regulator has approved an animal biotechnology product for both food and biomedical purposes.

What is intentional genomic alteration?

Intentional genomic alteration in animals means making specific changes to the genome of the organism using modern molecular technologies that are popularly referred to as genome editing or genetic engineering. However, there are other technologies that can be used to make IGAs in animals.

Such changes in the DNA sequence of an animal may be carried out for research purposes, to produce healthier meat for human consumption and to study disease resistance in animals among other reasons. One example is of using IGAs to make an animal more susceptible to certain diseases such as cancer, which helps researchers get a better understanding of the disease and develop new therapies to treat it.

The FDA maintains that the only difference between an animal with an IGA and one that does not have an IGA is that the IGA gives them a new trait or characteristic, such as faster growth or resistance to certain diseases.

Essentially, an IGA is inserted into an animal to change or alter its structure and function and the FDA makes sure that the IGA contained in the animal is safe for the animal and safe for anyone who consumes a product or food derived from the animal. Follow Express Explained on Telegram

What does FDAs recent approval mean?

The FDA made the announcement this week and allowed IGA in GalSafe pigs to eliminate a type of sugar found in mammals called alpha-gal. This sugar is present on the surface of these pigs cells and when they are used for products such as medicines or food (the sugar is found in red meats such as beef, pork and lamb), the sugar makes some people with Alpha-gal Syndrome (AGS) more susceptible to developing mild to severe allergic reactions.

Since GalSafe pigs may potentially be used to produce human medical products, IGA will help eventually free these products from detectable alpha-gal sugar, thereby protecting their human consumers from potential allergies.

According to the FDA, GalSafe pigs may be used to make the blood-thinning drug heparin.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Explained News, download Indian Express App.

IE Online Media Services Pvt Ltd

Read the rest here:
Explained: What US FDA nod for genetically modified pigs means - The Indian Express

WILLIAMSVILLE, N.Y., Dec. 17, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that it was granted a new U.S. patent related to the control of cannabinoid and terpene production in plants. This new intellectual property exclusively provides 22nd Century with unique and powerful tools to alter the cannabinoid biosynthesis pathway in hemp/cannabis plants.

"We are delighted to receive this patent, which is the result of work carried out by our own scientists. This important, new technology will allow us to genetically modify hemp/cannabis plants to modulate their cannabinoid and terpene profiles in order to tailor these plants therapeutic qualities and enhance the consumers hemp/cannabis experience," said Juan Sanchez Tamburrino, Ph.D., vice president of research & development at 22nd Century Group. "Our patent application describes eight promoters, which are essentially molecular on/off switches, covering all of the major steps in the cannabinoid biosynthesis pathway. Typically, developing hemp/cannabis plants with new cannabinoid or terpene profiles could take 10 to 20 years using traditional breeding methods. Now, with the combined technologies and know-how of 22nd Century and KeyGene, we expect to shorten the development timeline to create new, differentiated, hemp/cannabis plant lines in just 4 to 5 years. Doing so will provide the Company and its potential licensees and customers with significant competitive advantage as hemp/cannabis continues to penetrate the life science, consumer product, and pharmaceutical markets.

At 22nd Century Group, we take a scientific and solutions-oriented approach to advancing ground-breaking, plant-based technology. We are excited to secure this patent, and we believe that it demonstrates our unique and leading role in plant science innovation within the $100 billion global hemp/cannabis market, said James A. Mish, chief executive officer of 22nd Century Group.

The new patent, published as U.S. Patent No. 10,787,674 B2 and entitled "Trichome specific promoters for the manipulation of cannabinoids and other compounds in glandular trichomes," enables 22nd Century to develop and deliver new hemp/cannabis plants that are designed to produce cannabinoids more efficiently. The Company can potentially increase the yield of plants, stabilize the level of cannabinoids that are produced, and create custom cannabinoid profiles optimized for specific therapeutic uses. 22nd Century will also be able to potentially modulate the terpene levels within the plant increasing them to deliver new strains of cannabis for the adult-use/recreational market and reducing them to remove the odor and taste for improved application in foods and beverages.

Cannabinoids, such as CBD, CBC, and CBG, are valuable compounds that hold great promise for the development of new medicines and other therapeutic applications. Cannabis sativa is the only plant species that produces significant amounts of these compounds including more than one hundred different cannabinoids in varying quantities. In nature, cannabis plants restrict production of these potentially toxic compounds to the trichomes which are tiny hair-like stems and globes that grow on the surface of the plant. To successfully manipulate cannabinoids, the Companys new technology activates molecular promoters, on/off switches, specifically and only in the plants trichomes where the majority of cannabinoids are produced. These regulatory sequences dynamically enhance or restrict gene expression levels, controlling the expression of genetic information that leads to the production of cannabinoids.

About 22nd Century Group,Inc.22nd Century Group, Inc. (NYSE American: XXII) is a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene-editing, and modern plant breeding. 22nd Centurys primary mission in tobacco is to reduce the harm caused by smoking through the Companys proprietary reduced nicotine content tobacco cigarettes containing 95% less nicotine than conventional cigarettes. The Companys primary mission in hemp/cannabis is to develop and commercialize proprietary hemp/cannabis plants with valuable cannabinoid profiles and desirable agronomic traits.

Learn more atxxiicentury.com, on Twitter@_xxiicenturyand onLinkedIn.

Cautionary Note Regarding Forward-Looking StatementsExcept for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as anticipate, believe, consider, continue, could, estimate, expect, explore, foresee, goal, guidance, intend, likely, may, plan, potential, predict, preliminary, probable, project, promising, seek, should, will, would, and similar expressions. Actual results may differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in Risk Factors in the Companys Annual Report on Form 10-K filed on March 11, 2020 and on Quarterly Reports on Form 10-Q. All information provided in this release is as of the date hereof, and the Company assumes no obligation to publicly update or revise any forward-looking statements as a result of new information, future events, or otherwise, except as required by law.

Investor Relations & Media Contact:Mei KuoDirector, Communications & Investor Relations22nd Century Group, Inc.(716) 300-1221mkuo@xxiicentury.com

Read more:
22nd Century Group Achieves Breakthrough Hemp/Cannabis GMO Technology; Granted New Patent for Controlling Genes Responsible for Production of CBD,...

These concerns have proven to be well founded. Many species of insects no longer respond to the effects of pesticides. World pesticide use has increased dramatically, but the percentage of crops lost to pests has not declined. Insects consume as much as one-third of the Asian rice crop annually, and in the United States losses of fruit and vegetable crops from plant diseases may exceed 20 percent. Clearly, just pouring on more chemicals is no answer.

From Food Irradiation: Will It Keep the Doctor Away? November/December 1997:

Nearly 200 people in the US, most of them children or elderly, die each week from illnesses they contract from food. This spring, President Clinton called for new steps using cutting-edge technology to keep our food safe. One of the technologies that Clinton singles out is food irradiation.

It will probably take some truly traumatic E. coli outbreak before the food industry gets serious about irradiation, says James Tillotson, director of the Food Policy Institute at Tufts University. Without such a crisis, consumers wouldnt think of demanding irradiated food and companies that explore irradiation [would be] open to attacks by activist groups. No one is willing to get that kind of attention, he says, even when they might be doing the best thing for consumers.

From Why We Will Need Genetically Modified Foods, January/February 2014:

Plant scientists are careful to note that no magical gene can be inserted into a crop to make it drought tolerant or to increase its yieldeven resistance to a disease typically requires multiple genetic changes. But many of them say genetic engineering is a versatile and essential technique. Its an overwhelmingly logical thing to do, says Jonathan Jones, a scientist at the Sainsbury Laboratory in the U.K. The upcoming pressures on agricultural production, he says, will affect millions of people in poor countries. At the current level of agricultural production, theres enough food to feed the world, says Eduardo Blumwald, a plant scientist at the University of California, Davis. But when the population reaches nine billion? he says. No way, Jos.

Link:
From the archives - MIT Technology Review

Climate change will affect many agricultural crops, and field corn is likely no exception.

Field corn, the starchy cousin of sweet corn, is a globally important cereal grain used in livestock feed and other products. And it has an Achilles heel: unseasonably warm nights.

As nighttime temperatures rise, corn yields decline. These high temperatures affect an enzyme in maize responsible for storing starch. At higher nighttime temperatures, that enzyme, called PGD3, stops working, and the corn kernels will not produce as much starch, or will not properly develop, said Camila Ribeiro, a graduate of theUniversity of Florida (UF/IFAS) College of Agricultural and Life Sciences (CALS)and former postdoctoral researcher at theUF/IFAS Citrus Research and Education Center.

Over the next several decades, as we see climate change lead to higher nighttime temperatures, this could mean farmers wont be able to produce enough corn to stay in business, said Mark Settles, professor in theUF/IFAS horticultural sciences department. Thats a food supply issue and an economic problem.

But Ribeiro and Settles may have a solution. In a new study, they show that a new variety of field corn is productive even when nights are warm. This variety was developed via a novel genetic engineering technique that inserts a copy of a corn gene to make a protein in a new location in the plants cells. This finding could help inform traditional breeding efforts down the line.

To test how well their new corn variety fared in the heat, the researchers planted it during March and April at theUF/IFAS Plant Science Research and Education Unitlocated about 30 minutes south of the main UF campus in Gainesville. Compared to the March plantings, the corn planted in April experienced warmer nights temperatures during kernel development.

The results were striking: the new variety produced 40% more yield under higher temperatures.

In the field, we had plots planted with engineered and non-engineered plants. They were growing under the same conditions, same temperatures. As we harvested the field, we could see just how much bigger the corn ears were in the new variety under heat stresses. It was very exciting to see, said Ribeiro, who completed this research as part of her a doctoral studies in plant molecular and cellular biology at UF/IFAS CALS.

It was exciting because, for people like us who want to figure out how to grow food with climate change, this is a promising result,said Settles, who was Ribeiros dissertation adviser. Ribeiro now works at the Brazilian Agricultural Research Corporation (EMBRAPA) Maize & Sorghum in Brazil.

This new corn variety is more productive because the heat sensitive PGD3 enzyme that allows the plant to store starch is getting extra help.

PGD3 isnt the only enzyme in the cell that catalyzes its specific reaction. You also have PGD1 and PGD2. Unlike PGD3, 1 and 2 arent sensitive to heat, but they dont operate in the part of the cell where PGD3 operates, the amyloplast, which is the part of the plant cell that produces starch, Settles said. We wanted to find a way to move 1 and 2 into the amyloplast. Once there, we predicted they would be able to help kernels grow at higher temperatures.

Our study confirmed that when PGD1 and PGD2 proteins are relocated to the amyloplasts, it results in the characteristic we are looking for, heat resistance, Settles said.

The engineered genes open up the possibility of making new heat resistant varieties using traditional breeding techniques, the researchers say. Breeders could screen corn plants for heat-resistant forms of PGD3 to try to get the same effect.

Our study is an example of how genetic engineering techniques can speed up traditional plant breeding processes by giving breeders insight into how genes confer desired traits. Climate change is happening fast, and we need to develop plants that will adapt to this new environment as soon as possible, Settles said.

While such a corn variety may not be commercially available for several years, Ribeiro and Settles are hopeful that their plants will one day help feed a changing world.

Source: University of Florida

Go here to read the rest:
Florida Researchers Develop Corn that Can Weather Warming Planet - Seed World

When did you first start using AAV vectors in your gene therapy work?

It came about 10 years ago when I was helping the Gates Foundation develop an approach for preventing HIV. Any attempt to use a traditional vaccine, where you inject a component of the virus to activate the immune system to develop proteins such as antibodies, had been challenging for HIV. Regardless of what you used to immunizebecause the virus changed so muchmost of it would escape. Once the field realized that, we started to look at other approaches, and it turns out its possible in the lab to engineer an antibody that could be effective against many types of HIV.

HIV represents a different type of pandemic than COVID-19. When did you turn to AAV vectors as a potential approach for other kinds of pandemics?

About eight years ago I started thinking about this as a countermeasure for a pandemic. The pandemics that we worry about are primarily transmitted through a respiratory route. If it were direct contact like Ebola virus, its not as dangerous because you can avoid touching one another. But if you cant even be in the same room, thats a problem.

Respiratory viruses enter our body through the nose and throat. Thats how we get infected. We proposed delivering the vector through a nasal mist or spray to engineer the cells that line the nose and throat to express the antibody. If you can localize this at that site to prevent the virus from going farther, then you dont need the whole body to express the antibodies.

The antibodies youre using, called casirivimab and imdevimab, are monoclonal antibodies, meaning they were created in a lab. Can you describe how they work?

Regeneron developed these. Theyre highly active and potent against SARS-CoV-2. For treatment, antibodies can be useful. If youre starting to get sick, you get an infusion or two of the antibodies and then you dont get sicker. But what do you do with 99% of the population who isnt sick and never gets sick? Our idea was to use an AAV vector expressing the antibodies to engineer someones cells to produce the antibodies. If we do this right, the expression could go on for a long period of time. Its a one-time vector infusion.

We were able to show in animal models that an AAV sprayed into the nose that expresses an antibody is effective against flu virus that causes respiratory diseases and has the potential to cause a pandemic. The treated animals were completely protected when exposed to flu virus. Its all about having the right antibody and then engineering a delivery system to have this blockage. We call it a bioshield. It could be a way to stop COVID-19 in its tracks.

Would this approach replace COVID-19 vaccines or be used in conjunction with them?

Theoretically, it could be used in place of a vaccine, but I suspect that traditional vaccines are going to succeed for a lot of people. We see our approach being deployed in individuals for which traditional vaccines may not work as well, patients with diseases that compromise their immune system such as cancer, patients who are on immune-modulating drugs, or even the elderly.

Early data seem to suggest that the elderly have some level of response to the active COVID-19 vaccine, but, like with many other vaccines, older people dont mount the same immune response as those who are younger. That said, I dont see any reason why receiving a traditional vaccine would preclude one from using our nasal spray because they do two different things.

The other possibility is that the COVID-19 vaccines we have become less effective because the virus changes. I dont think this will happen, and I hope it doesnt, but, if it does, the question becomes, Would the antibodies that Regeneron created become a backup? When we roll out an active vaccine based on a single spike protein into large populations, it creates pressure on the SARS-CoV-2 to change and potentially become resistant. I hope a variant doesnt emerge, but I do think it behooves us to have some redundancy in place to squelch a potential second wave due to resistant coronaviruses.

What is your projected timeline?

We are conducting one final experiment over the holiday break and in early January before we submit our request to the FDA for clinical trials. Weve had discussions with the FDA and have already done some of the initial testing, including safety testing in nonhuman primates, as well as preparing to manufacture the product. Conducting this in the Gene Therapy Program is beneficial since we are comfortable with AAV vectors and moving them into clinical trials. We support up to eight traditional AAV gene therapy programs a year, and we have the staff and technology to move pretty quickly.

If we get the go in January, I think our technology could contribute to the global response in eliminating COVID-19. And you have to understand, until we eliminate it globally, we havent actually eliminated it.

View original post here:
Repurposing a proven gene therapy approach to treat, prevent COVID-19 - Penn Today

Databridgemarketresearch.com Present Global CRISPR gene-editing Market Industry Trends and Forecast to 2027 new report to its research database. This research report understands the current and future of the market in both developed and emerging markets. The Global CRISPR gene-editing Market report assists in realigning the business strategies by highlighting the business priorities. It throws light on the segment expected to dominate the industry and market. It forecast the regions expected to witness the fastest growth. This report is a collection of pragmatic information, quantitative and qualitative estimation by industry experts, the contribution from industry across the value chain. Furthermore, the report also provides the qualitative results of diverse market factors on its geographies and Segments.

This Global CRISPR gene-editing Market tracks the major market events including product launches, development trends, mergers, acquisition and the innovative business strategies opted by key market players. The Global CRISPR gene-editing Market report also focuses on industry-specific drivers, restraints, opportunities and challenges in the market. The global market is bifurcated into sub-segments that can provide classified data regarding the latest trends in the market.

Global CRISPR gene-editing Market is rising gradually with a healthy CAGR of 23.35 % in the forecast period of 2019-2026. Growing prevalence of cancer worldwide and expanding the application of CRISPR technology by innovative research from the different academic organizations are the key factors for market growth.

Get a Free Sample Copy of the Report @ (Use Corporate email ID to Get Higher Priority) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-crispr-gene-editing-market

Few of the major competitors currently working in the global CRISPR gene-editing market are Applied StemCell, ACEA BIO, Synthego, Thermo Fisher Scientific Inc, GenScript, Addgene, Merck KGaA, Intellia Therapeutics, Inc, Cellectis, Precision Biosciences, Caribou Biosciences, Inc, Transposagen Biopharmaceuticals, Inc, OriGene Technologies, Inc, Novartis AG, New England Biolabs among others

Global CRISPR Gene-Editing Market By Therapeutic Application (Oncology, Autoimmune/Inflammatory), Application (Genome Engineering, Disease Models, Functional Genomics and Others), Technology (CRISPR/Cas9, Zinc Finger Nucleases and Others), Services (Design Tools, Plasmid and Vector, Cas9 and g-RNA, Delivery System Products and Others), Products (GenCrispr/Cas9 kits, GenCrispr Cas9 Antibodies, GenCrispr Cas9 Enzymes and Others), End-Users (Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, Contract Research Organizations and Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2026

Global CRISPR Gene-Editing Research Methodology

Data Bridge Market Research presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers.

Market Drivers

Market Restraints

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: CRISPR Gene-Editing Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

Chapter 4: CRISPR Gene-Editing Market, By Region

Chapter 5: Company Profile

Business Overview

Financial Data

Product Landscape

Strategic Outlook

SWOT Analysis

Complete report is available (TOC) @https://www.databridgemarketresearch.com/toc/?dbmr=global-crispr-gene-editing-market

Key Developments in the Market:

In April 2019, GenScript has launched Single-stranded DNA Service for CRISPR-based Gene Editing which help the key researchers to have access on the high quality, pure ssDNA for CRISPR-based gene insertion and hence can accelerate the development of gene as well as cell therapy for cancer immunotherapy

In February 2018, Cellectis has received two U.S. patents (US#9,855,297 and US#9,890,393) entiled as Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system for CRISPR Use in T-Cells. The U.S. grant of these patents, the company can generate revenue by out-licensing the products to the pharma companies that are ready to use CRISPR technologies in T-cells

Competitive Analysis:

Global CRISPR gene-editing market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of CRISPR gene-editing market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Corporatesales@databridgemarketresearch.com

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Go here to read the rest:
Global CRISPR gene-editing Market 2020- Industry Analysis Trends, Market Analysis, CAGR Values and Country Level Demand To Forecast by 2027 - The...